Hengrui lost its 200 billion-dollar market capitalization "share god" pit crying nearly 30,000 shareholders

Last November in the A-share market, Hengrui Pharmaceuticals, Kangmei Pharmaceuticals, Yunnan White Pharmaceuticals, Shanghai Lais, Huada Gene, Fosun Pharma 6 pharmaceutical stock market value of more than 100 billion scale. As of the close of trading on December 26, 2018, only Hengrui Pharmaceuticals and Meirui Medical had a market capitalisation of 100 billion, while Shanghai Lais, the former "share god", and Huada Gene, which is second only to Maotai in share prices, seemed to be further away from the market capitalisation of 100 billion yuan.
2018 is coming to an end, and for pharmaceutical stocks, many people are believed to have "guessed the beginning, but not the end." In the first half of the year, pharmaceutical stocks were on a strong trend, and in July, the release of "I Am Not a Drug God" seems to have become a watershed in the industry, causing the entire pharmaceutical industry, and even the country's high attention. Industry earthquake also followed, long-term biological vaccine fraud, the United States health "fake doctor door" ... Recently with the volume of procurement boots landing, the state to combat the health care fund fraud and other factors, pharmaceutical stocks have been hit hard.
november last year in the A-share market, Hengrui Pharmaceuticals, Kangmei Pharmaceuticals, Yunnan White Pharmaceuticals, Shanghai Lais, Huada Gene, Fosun Pharma six pharmaceutical stock market value of more than 100 billion scale. On October 11 this year, U.S. and European stock markets fell sharply, Asia-Pacific stocks fell sharply, the Shanghai index fell below 2,600 points, the Shanghai index closed on December 26th, the Shanghai index lost 2,500 points, the market value of only Hengrui Pharmaceuticals and Meirui Medical. And once the "share god" Shanghai Lais and the share price after Maotai Huada gene fell out of the pharmaceutical stock market value TOP10, seems to be a hundred billion yuan market value of the further away.pharmaceutical stock market value TOP10
pharmaceutical stocks a brother "back to the original shape"? As of November 3, 2017,
Hengrui Pharmaceuticals became the first pharmaceutical stock with a market capitalization of more than 200 billion yuan;Hengrui Pharmaceuticals coherence evaluation of supplementary applications
pharmaceutical stocks, although the market value of a brother suffered a "severe blow", but can not stop the pace of its progress. In the first three quarters of this year, Hengrui Pharmaceutical invested 1,737 million yuan in research and development, up 39.68 percent year-on-year, and 1,759 million yuan in research and development in 2017. Up to now, Hengrui Pharmaceutical's inhalation land fluorane, injection with yew alcohol (albumin binding type), hydrochloride bromine rope tablets, hydrochloric acid Tansorosin slow release capsules, Ebershatan tablets a total of 5 varieties through or as if through consistency evaluation. In terms of consistent evaluation of supplementary applications, Hengrui Pharmaceuticals has as many as 14 varieties, involving 19 receiving numbers.
Recently, Hengrui Pharmaceuticals' drugs were frequently approved, on December 15, the company received approval from the State Drug Administration to issue the injection of Parecheb sodium "Drug Registration Approval", on December 19, its subsidiary Ruishi Biopharmaceutical Co., Ltd. submitted SHR030 to the FDA 2 clinical trial applications were accepted, and on December 22nd, its anti-PD-1 antibody SHR-1210 in association with Apatinib's first-line treatment of hepatocellular carcinoma, the International Multi-Center Phase III clinical trial was communicated with the FDA, and the trial will be conducted simultaneously in the United States, Europe and China... Hengrui Pharmaceuticals said that in the future, the company will continue to steadily promote research and development innovation and the internationalization of preparation products, while also focusing on product structure optimization and upgrading to ensure sustainable growth of the company's performance."share god" after the resumption of trading 10 stop
recently, after the resumption of trading "share god" Shanghai Laishi can be said to be an eventable autumn. On December 7th Shanghai Laishi resumed trading, and announced plans for a restructuring, in which Shanghai Laishi plans to issue shares to buy all or part of GDS held by Kirifu, as well as a 100% stake in Tiancheng Germany held by Tiancheng's German shareholders, for a total transaction price of about Rmb39,114m. However, the nearly 40 billion yuan merger and acquisition does not seem to have been able to make a strong impact, after the resumption of trading share prices experienced 10 consecutive stops, after December 25 and 26 consecutive gains and stops, the market value from 91.7 billion before the resumption of trading to 38.9 billion (as of december 26 closing).
December 17th, Shanghai Laix received a letter of inquiry from Shenzhen Stock Exchange, which raised nine questions about the restructuring plan issued on the 7th and asked for written explanation. On December 19th, Shanghai Raith issued an unusually volatile announcement on stock trading, the third time since its resumption of trading that type of announcement, and on the same day, media reports indicated that Shanghai Raith had defaulted due to the fact that its pledge stock price was below the closing line and had failed to meet its obligations to fill positions, and that the company's controlling shareholder, Laix China Limited, was at risk of passively reducing its holdings of the company's shares. Shares in Shanghai's Raith fell in a row, while individual shareholders suffered heavy losses, with 275,000 shareholders losing more than 2.3 million yuan, the most of any shareholder loss this year.
the first three quarters of this year, Shanghai Raith's net profit was RMB1,293 million, down 237.51 percent year-on-year, and it expects to lose RMB961 million to RMB1.212 billion for the full year. Shanghai Lais said that the company's main business operations are stable, due to fluctuations in the capital market, the company's securities investment caused a large loss, which is the main cause of net profit losses.
this time, Shanghai Laix to face a lot of crises, mergers and acquisitions can proceed smoothly? After returning to the main business, can the performance turn a loss? All these questions need to be answered by Shanghai Les.share price was second only to Maotai, Huada gene "myth" burst
on July 14, 2017, Huada gene listed on the market, the number of consecutive boards as many as 18, November 14, the market value of the market exceeded 100 billion, its share price once climbed to 2 The high of 60 yuan, second only to Maotai, on July 16, 2018, 206 million restricted shares were lifted, the day the opening fell, on October 23, the closing price fell below 50 yuan, a year after the listing, the market value evaporated 80 billion yuan. As of the close of trading on December 26, the market value was 22 billion yuan.
recently, Huada Gene has been questioned about illegal practice of medicine, director departure, reduction of holdings and a series of events, so that its share price fell. As early as July 17, 19 and 23, Huada Gene issued three increase announcements, the total amount of increase of 190 million yuan, the main body of the increase includes the company's chairman, directors, senior executives and so on. On December 14th, Huada Gene announced the completion of the plan to increase the shares of some directors and senior managers of the company, saying that between July 18th and December 13th, some directors and senior managers of the company had increased their holdings of the company's shares by a cumulative amount of 31.18 million yuan, and had completed the plan to increase their holdings.
In fact, Huada gene's "small financial reporting market value" at the beginning of the listing has attracted the attention of the industry, since this year, Huada gene's market value continued to shrink, currently hovering around 20 billion yuan, compared with the peak of the decline of about 80%. Huada Gene's main operating income comes from the four major sectors of reproductive health, complex diseases, basic research and drug research and development, of which the top three sectors account for more than 90% of total operating income. In the first three quarters of this year, Huada Gene's revenue was RMB1,814 million, up 25.39% YoY, and net profit was RMB320 million, up 2.48% YoY.
" stock 'black swan' incident is accidental, the impact on the industry is not strong, often from policy changes this is the pharmaceutical industry's real 'black swan'. "Some industry analysts pointed out that in recent years, the pharmaceutical industry's policy intensive introduction, from the policy landing point and content, medical reform is to reduce drug prices as a breakthrough, straighten out the price system of medical institutions "cage for birds", medical insurance control fees are the first priority is to reduce drug prices, and fee reduction will be one of the main policy tone of the pharmaceutical industry in the future. (Mi Net)